Applied Molecular Transport Inc. (NASDAQ:AMTI – Get Rating) – Equities researchers at SVB Leerink lowered their Q2 2022 earnings per share estimates for shares of Applied Molecular Transport in a research report issued on Monday, May 9th. SVB Leerink analyst J. Schwartz now forecasts that the company will earn ($0.79) per share for the quarter, down from their prior estimate of ($0.76). SVB Leerink also issued estimates for Applied Molecular Transport’s Q3 2022 earnings at ($0.72) EPS, Q4 2022 earnings at ($0.73) EPS, FY2022 earnings at ($3.32) EPS and FY2023 earnings at ($3.60) EPS.
Applied Molecular Transport (NASDAQ:AMTI – Get Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.35).
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new stake in shares of Applied Molecular Transport in the 3rd quarter valued at $4,475,000. Marshall Wace LLP increased its position in shares of Applied Molecular Transport by 36.5% in the 3rd quarter. Marshall Wace LLP now owns 11,522 shares of the company’s stock valued at $298,000 after buying an additional 3,081 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of Applied Molecular Transport in the 3rd quarter valued at $257,000. Deutsche Bank AG increased its position in shares of Applied Molecular Transport by 28.9% in the 3rd quarter. Deutsche Bank AG now owns 19,789 shares of the company’s stock valued at $512,000 after buying an additional 4,436 shares in the last quarter. Finally, EPIQ Capital Group LLC increased its position in shares of Applied Molecular Transport by 2.8% in the 3rd quarter. EPIQ Capital Group LLC now owns 9,009,055 shares of the company’s stock valued at $233,064,000 after buying an additional 244,335 shares in the last quarter. Institutional investors and hedge funds own 71.34% of the company’s stock.
In other Applied Molecular Transport news, Director Aaron Vandevender bought 4,112 shares of the company’s stock in a transaction on Monday, February 28th. The stock was bought at an average price of $6.51 per share, for a total transaction of $26,769.12. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 25.40% of the stock is currently owned by corporate insiders.
About Applied Molecular Transport (Get Rating)
Applied Molecular Transport Inc, a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications.
- Get a free copy of the StockNews.com research report on Applied Molecular Transport (AMTI)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Applied Molecular Transport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Molecular Transport and related companies with MarketBeat.com's FREE daily email newsletter.